Ernexa Therapeutics Inc. Sale of Stock, Consideration Received on Transaction
Ernexa Therapeutics Inc. (ERNA) had Sale of Stock, Consideration Received on Transaction of $5.90 thousand as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Equity
us-gaap:SaleOfStockConsiderationReceivedOnTransaction · last filed 2026-08-06
- 2026-06-30: Sale of Stock, Consideration Received on Transaction $5.90K.
- 2026-03-13: Sale of Stock, Consideration Received on Transaction $50.00M.
| Period end | Sale of Stock, Consideration Received on Transaction |
|---|---|
| 2026-06-30 | $5.90K 10-Q · filed 2026-08-06 |
| 2026-03-13 | $50.00M 10-Q · filed 2026-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |